Hua Medicine (Shanghai) Ltd. (2552.HK) HKSE

4.37

-0.12(-2.67%)

Updated at September 08 03:45PM

Currency In HKD

Hua Medicine (Shanghai) Ltd.

Address

Building A

Shanghai,

China

Phone

862158869997

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

168

First IPO Date

September 14, 2018

Key Executives

NameTitlePayYear Born
Dr. Li Chen Ph.D.Founder, Chief Executive Officer & Executive Director10.61M1964
Dr. Yi Zhang M.D., Ph.D.Senior Vice President of Pharma Development, Chief Medical Officer – China and Executive Director4.56M1976
Mr. Chien Cheng Lin J.D.Executive Vice President & Chief Strategy Officer5.95M1971
Mr. Yu LuVice President of Sales & Marketing0N/A
Mr. Chengde WangHead of IR01948
Dr. Fuxing Tang Ph.D.Chief Technology Officer, Vice President of Chemical Manufacturing Control Department and Head of R&D in USA01967
Mr. Ying Xie M.B.A.Vice President of Quality Assurance Division & Chief Quality Officer0N/A
Dr. Changhong Li Ph.D.Chief Scientific Officer01969
Ms. Wing Yan Yuen FCIS, FCSCompany Secretary01970

Description

Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.